Actively Recruiting
Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD
Led by University of Haifa · Updated on 2025-03-27
53
Participants Needed
3
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.
CONDITIONS
Official Title
Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with PTSD according to DSM-IV or DSM-5 criteria
- Currently treated at the outpatient facilities of Lev HaSharon Netanya Adult Clinic
- Aged between 20 and 60 years
- PTSD diagnosis made at least one month before study inclusion
- No current re-exposure to the traumatic event
- Any psychotropic drug therapy is at a stable dose for at least one month before the study
You will not qualify if you...
- Comorbid major psychiatric disorders such as psychotic disorder, unipolar or bipolar disorder, borderline personality disorder, or active suicidal ideation
- Diagnosis of ADHD
- Significant or severe systemic diseases limiting normal activity, e.g., autoimmune disease, AIDS, or renal failure
- Cardiovascular diseases including hypertension, AV block, bradycardia, or conduction disorders
- Severe life-threatening diseases such as acute myocardial infarction, respiratory failure, or cancer
- Nervous system impairments like multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, or stroke
- Previous or current severe traumatic brain injury
- Glaucoma
- Impaired hearing
- Pregnancy or breastfeeding at study inclusion
- Active substance dependency including regular medical cannabis use
- Use of steroid medication within two months prior to study
- Use of medications affecting central nervous system function
- Failure to complete all research steps
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Emek Medical Center
Afula, Israel
Actively Recruiting
2
University of Haifa
Haifa, Israel
Actively Recruiting
3
Lev HaSharon Mental Health Center
Netanya, Israel
Actively Recruiting
Research Team
A
Avi Avital, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here